experienced significant blood loss as a result and required multiple blood product transfusions and extended hospital stay.; Got pregnant; experienced delayed ovulation; low progesterone; abnormal placental development; had to deliver early due to growth restriction; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 34-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 20Sep2021 as dose 2, single (Lot number: FE3592) at the age of 34 years for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: BNT162b2 (Dose Number: 1, Batch/Lot No: FC3182), administration date: 29Aug2021, when the patient was 34-year-old, for COVID-19 immunization. The following information was reported: PREGNANCY (caused and prolonged hospitalization, congenital anomaly) with onset Nov2021, outcome "recovered with sequelae", described as "Got pregnant"; PLACENTAL DISORDER (caused and prolonged hospitalization, congenital anomaly) with onset Nov2021, outcome "recovered with sequelae", described as "abnormal placental development"; OVULATION DELAYED (caused and prolonged hospitalization, congenital anomaly) with onset Nov2021, outcome "recovered with sequelae", described as "experienced delayed ovulation"; HAEMORRHAGE (caused and prolonged hospitalization, congenital anomaly, medically significant) with onset Nov2021, outcome "recovered with sequelae", described as "experienced significant blood loss as a result and required multiple blood product transfusions and extended hospital stay."; PREMATURE DELIVERY (caused and prolonged hospitalization, congenital anomaly) with onset Nov2021, outcome "recovered with sequelae", described as "had to deliver early due to growth restriction"; PROGESTERONE DECREASED (caused and prolonged hospitalization, congenital anomaly) with onset Nov2021, outcome "recovered with sequelae", described as "low progesterone". The patient was hospitalized and prolonged hospitalization for haemorrhage, pregnancy, ovulation delayed, progesterone decreased, placental disorder, premature delivery (hospitalization duration: 3 day(s)). The events "experienced significant blood loss as a result and required multiple blood product transfusions and extended hospital stay.", "got pregnant", "experienced delayed ovulation", "low progesterone", "abnormal placental development" and "had to deliver early due to growth restriction" required physician office visit. The patient underwent the following laboratory tests and procedures: Ultrasound scan: Unknown Results. Therapeutic measures were taken as a result of haemorrhage, pregnancy, ovulation delayed, progesterone decreased, placental disorder, premature delivery.  Clinical course: Patient did not receive any other vaccine in four weeks. Patient had received other medications in two weeks. Patient had no known allergies. Patient got pregnant shortly after vaccination, experienced delayed ovulation and low progesterone despite prior normal healthy pregnancies, had abnormal placental development, required multiple hormonal medications to support the pregnancy, high risk consults and ultrasounds, and had to deliver early due to growth restriction, subsequently had surgery to remove placenta as adhered to uterine wall and experienced significant blood loss as a result and required multiple blood product transfusions and extended hospital stay. Currently patient still being monitored as to whether her uterus has healed or if she would require hysterectomy or other surgeries and the inability to have future pregnancies/children as a result. Patient did not have COVID prior vaccination, and she did not test COVID post vaccination.